Stocks and InvestingStocks and Investing
Wed, April 5, 2023
Tue, April 4, 2023
Mon, April 3, 2023
Sat, April 1, 2023
Fri, March 31, 2023

Eliana Merle Maintained (BNTX) at Hold with Decreased Target to $153 on, Mar 31st, 2023


Published on 2024-10-28 02:31:05 - WOPRAI, Eliana Merle
  Print publication without navigation


Eliana Merle of UBS, Maintained "BioNTech SE" (BNTX) at Hold with Decreased Target from $168 to $153 on, Mar 31st, 2023.

Eliana has made no other calls on BNTX in the last 4 months.



There are 8 other peers that have a rating on BNTX. Out of the 8 peers that are also analyzing BNTX, 5 agree with Eliana's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Yaron Werber of "TD Cowen" Maintained at Hold with Decreased Target to $130 on, Tuesday, March 28th, 2023
  • Matthew Korn of "Morgan Stanley" Maintained at Hold with Decreased Target to $150 on, Tuesday, March 28th, 2023
  • Chris Shibutani of "Goldman Sachs" Maintained at Hold with Decreased Target to $140 on, Tuesday, March 28th, 2023
  • Jessica Fye of "JP Morgan" Maintained at Hold with Decreased Target to $142 on, Wednesday, February 8th, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $216 on, Tuesday, January 24th, 2023


These are the ratings of the 3 analyists that currently disagree with Eliana


  • Robert Burns of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $210 on, Thursday, March 30th, 2023
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $194 on, Tuesday, March 28th, 2023
  • Bill Selesky of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $203 on, Tuesday, March 28th, 2023